A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: HER-2 pulsed DC1|DRUG: trastuzumab|DRUG: pertuzumab
Sponsor: H. Lee Moffitt Cancer Center and Research Institute